# Comparison of pigment epithelium detachment composition indices between neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

**Authors:** Stavan V. Shah, Sumit Randhir Singh, Amrish Selvam, Sanjana Harihar, Yash Parmar, Rubble Mangla, Supriya Arora, Kiran K. Vupparaboina, Ramesh Venkatesh, Jay Chhablani

PMC · DOI: 10.1186/s40942-023-00512-6 · 2024-02-15

## TL;DR

This study compares changes in pigment epithelium detachment composition in two eye diseases over a year of treatment.

## Contribution

The study introduces a new method to analyze fibrous components in pigment epithelium detachment using OCT imaging.

## Key findings

- PEDCI-F increased in most eyes with n-AMD and PCV after 12 months of treatment.
- Improved visual acuity was linked to increased PEDCI-F in n-AMD but not in PCV.
- Eyes with increased PEDCI-F required fewer anti-VEGF injections.

## Abstract

To compare changes in the fibrous component of pigment epithelium detachment composition indices (PEDCI-F) in neovascular age-related macular degeneration (n-AMD) and polypoidal choroidal vasculopathy (PCV) over 12 months.

This was a retrospective chart review of treatment-naïve n-AMD and PCV eyes treated with anti-vascular endothelial growth factor (anti-VEGF) agents. Optical coherence tomography (OCT) images were recorded at baseline and at 3, 6, and 12 months. OCT images were processed by filtering followed by pigment epithelium detachment (PED) segmentation and analysis of PED lesion heterogeneity based on the composition (PEDCI-F).

A total of 74 eyes with n-AMD (36) and PCV (38) were included. Overall, PEDCI-F increased minimally in both n-AMD and PCV groups (both p > 0.05). The majority, i.e., 58.3% and 60.5%, of n-AMD and PCV eyes, respectively, showed an increase in PEDCI-F at 12 months. An increase in PEDCI-F was associated with improved BCVA logMAR (n-AMD, r = -0.79; p < 0.001 and PCV, r = − 0.06; p = 0.74) and the need for fewer anti-VEGF injections (n-AMD, r = − 0.53; p < 0.001 and PCV, r = − 0.09; p = 0.58).

PEDCI-F increases in the majority of eyes with n-AMD and PCV through 12 months following treatment with anti-VEGF injections. This group had better visual acuity compared to the other subset with reduction in PEDCI-F requiring more anti-VEGF injections and worse visual acuity, possibly due to fibrovascular PED (FVPED) collapse and atrophy or a relative increase in other PEDCI constituents at 12 months.

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** PCV (MESH:D000092342), atrophy (MESH:D001284), FVPED (MESH:D012163), n-AMD (MESH:D008268)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC10868073/full.md

---
Source: https://tomesphere.com/paper/PMC10868073